News
Feed
Events
Feed
News
+ Events
Feed

sterna biologicals GmbH & Co. KG

  • Land Deutschland

Aktuelle News

14 Dezember 2021

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

sterna biologicals announces dosing of first patient in phase IIa proof-of-concept study with SB010 in moderate to severe asthma

23 November 2021

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA COMBINING A NOVEL ANTISENSE-BASED TREATMENT WITH A DIGITAL THERAPY

7 Januar 2021

15:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A – 2nd closing private placement

26 Mai 2020

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

Sterna biologicals secures EUR 12.0 million (approx. USD 13.0 million) in private placement

7 November 2019

10:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

Sterna biologicals to attend international partnering and investor conferences in November

25 Juli 2019

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

sterna biologicals invited to present at the Goodwin – Solebury Trout – NASDAQ European Biotech Investor Day 2019

8 Juli 2019

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

sterna biologicals strengthens management team to progress towards phase IIb development.

18 März 2019

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

Sterna Biologicals holds Scientific Advisory Board meeting at 14th Congress of ECCO to advance phase IIb clinical development program of SB012 in Ulcerative Colitis

12 März 2019

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

Sterna Biologicals holds Scientific Advisory Board meetings to advance phase IIb clinical development program of SB010 in asthma

7 Januar 2019

15:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

Sterna biologicals prepares for phase IIb clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis

17 Oktober 2018

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

STERNA BIOLOGICALS TO ATTEND BIO-EUROPE(R) 2018 24th ANNUAL INTERNATIONAL PARTNERING CONFERENCE

5 September 2018

14:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

Successful device feasibility study with sterna biological’s asthma drug candidate SB010 enable selection of optimal nebulizers for late-stage development and commercialization

5 Juni 2018

15:32 Corporate

sterna biologicals GmbH & Co. KG

Corporate

STERNA BIOLOGICALS PRÄSENTIERT DETAILLIERTE ERGEBNISSE AUS EINER ERFOLGREICHEN PHASE-2a-STUDIE MIT DER GATA-3-SPEZIFISCHEN DNAzyme-FORMULIERUNG SB012 IN PATIENTEN MIT COLITIS ULCEROSA

29 Mai 2018

15:00 Corporate

sterna biologicals GmbH & Co. KG

Corporate

STERNA BIOLOGICALS GIBT DIE PRÄSENTATION VON DATEN DER GATA-3-SPEZIFISCHEN DNAzyme-FORMULIERUNG SB012 AUF DER DIGESTIVE DISEASE WEEK(R) BEKANNT

19 April 2018

10:00 Corporate

sterna biologicals GmbH & Co. KG

Corporate

STERNA BIOLOGICALS GIBT DIE VERÖFFENTLICHUNG VON SB010 PHASE IIA DATEN IN RESPIRATORY RESEARCH BEKANNT

19 Februar 2018

12:00 Corporate

sterna biologicals GmbH & Co. KG

Corporate

sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS ZEIGT PHASE-2a-STUDIENDATEN ZUR SICHERHEIT UND WIRKSAMKEIT DER GATA-3 SPEZIFISCHEN DNAzyme-FORMULIERUNG SB012 IN PATIENTEN MIT COLITIS ULCEROSA

10:00 Corporate EN

sterna biologicals GmbH & Co. KG

Corporate
EN

sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS REPORTS PHASE 2a STUDY DATA DEMONSTRATING EFFICACY OF ITS GATA-3 SPECIFIC DNAZyme FORMULATION SB012 IN PATIENTS WITH ULCERATIVE COLITIS

1 Februar 2018

14:00 Corporate

sterna biologicals GmbH & Co. KG

Corporate

STERNA BIOLOGICALS NIMMT IM ERSTEN HALBJAHR 2018 AN VERSCHIEDENEN INTERNATIONALEN KONFERENZEN TEIL

8 Januar 2018

10:05 Corporate

sterna biologicals GmbH & Co. KG

Corporate

STERNA BIOLOGICALS ERNENNT CHRISTIAN PANGRATZ ZUM CHIEF EXECUTIVE OFFICER

Anstehende Events

Keine Events gefunden